Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse

Leukemia volume 29, pages 1952–1954 (2015)Cite this article

Subjects

Long-term remission in acute myeloid leukemia (AML) is generally not durable only being achieved in <50% of patients.1 Consequently there is a need to establish new treatments to prevent relapse. A promising approach is to augment the anti-tumor immune response in these patients; however, it is well established that overexpression of immunosuppressive molecules such as CD200 on the surface of AML cells directly suppresses the antitumor response.2, 3, 4 Nevertheless, blocking CD200:CD200R, only partially restores T-cell activity, suggesting that alternative immunosuppressive mechanisms need to be explored if the antitumor response in AML is to be optimally exploited.5

Recently, promising clinical outcomes using humanized antibodies targeting PD-1 have been reported for melanoma and even for non-small cell lung cancer.6 PD-1 suppresses immunological function via interaction with its cognate ligand PD-L1 (aka B7-H1, CD274) and previous work has indicated that PD-L1 may also suppress immunological function in AML.7, 8 Here we investigate whether the PD-1:PD-L1 axis cooperates with CD200 in mediating immunosuppression in AML patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Shah A, TM-L Andersson, Rachet B, Björkholm M, Lambert PC . Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol 2013; 162: 509–516.

    Article  Google Scholar 

  2. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia 2012; 26: 2146–2148.

    Article  CAS  Google Scholar 

  3. Coles SJ, Wang ECY, Man S, Hills RK, Burnett AK, Tonks A et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 2011; 25: 792–799.

    Article  CAS  Google Scholar 

  4. Coles SJ, Hills RK, Wang ECY, Burnett AK, Man S, Darley RL et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia 2012; 26: 2148–2151.

    Article  CAS  Google Scholar 

  5. Norde WJ, Hobo W, van der Voort R, Dolstra H . Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 2012; 120: 728–736.

    Article  CAS  Google Scholar 

  6. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA . Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract 2014 doi:10.1177/1078155214538087.

    Article  Google Scholar 

  7. Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 2010; 59: 1839–1849.

    Article  CAS  Google Scholar 

  8. Ahmad SM, Svane IM, Andersen MH . The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J 2014; 4: e230.

    Article  CAS  Google Scholar 

  9. Schalper KA . PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014; 3: e29288.

    Article  Google Scholar 

  10. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132–2137.

    Article  CAS  Google Scholar 

  11. Beatty GL, Smith JS, Reshef R, Patel KP, Colligon TA, Vance BA et al. Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation. Clin Cancer Res 2009; 15: 4944–4953.

    Article  CAS  Google Scholar 

  12. Santegoets SJAM, Turksma AW, Suhoski MM, Stam AGM, Albelda SM, Hooijberg E et al. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J Transl Med 2013; 11: 37.

    Article  CAS  Google Scholar 

  13. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S . Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 2005; 114: 606–612.

    Article  CAS  Google Scholar 

  14. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117: 4501–4510.

    Article  CAS  Google Scholar 

  15. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G . Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73: 3591–3603.

    Article  CAS  Google Scholar 

  16. Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007; 21: 566–568.

    Article  CAS  Google Scholar 

  17. Sun W-J, Li X . B7-H1, a prognostic factor for patient’s response to therapy of acute myeloid leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2012; 20: 1332–1335.

    CAS  PubMed  Google Scholar 

  18. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS . Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008; 180: 699–705.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded by Leukaemia and Lymphoma Research UK and NISCHR, UK. RR is a CU/MRC UK funded student.

Author Contributions

SJC designed and performed the experiments, analyzed all data and cowrote the manuscript. MNG assisted with PD-L1 cloning and retroviral transduction. RR assisted with 7E7 T-cell expansion. SK and AKB provided resources and clinical insight. SM, AT and RLD contributed to experimental design and co-wrote the manuscript.

Author information

Author notes

  1. S Man, A Tonks and R L Darley: These authors contributed equally to this work.

Authors and Affiliations

  1. Institute of Science and the Environment, University of Worcester, Worcester, UK

    S J Coles

  2. Department of Haematology, Institute of Cancer and Genetics, School of Medicine, Cardiff University, Wales, UK

    S J Coles, M N Gilmour, R Reid, S Knapper, A K Burnett, S Man, A Tonks & R L Darley

Authors
  1. S J Coles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M N Gilmour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Knapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A K Burnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Man
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Tonks
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R L Darley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R L Darley.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coles, S., Gilmour, M., Reid, R. et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29, 1952–1954 (2015). https://doi.org/10.1038/leu.2015.62

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.62

This article is cited by

Search

Advanced search

Quick links